Xeris Biopharma reports cortisol normalization with Recorlev in Cushing's syndrome case study
XERS•Xeris Biopharma announced a case study showing normalized cortisol levels and improved cardiometabolic health in a patient with difficult-to-control diabetes. The study is scheduled for presentation October 15-16, 2026.
1. Case study presentation
Xeris Biopharma announced a Recorlev case study showing normalized cortisol levels and improved cardiometabolic health in a patient with difficult-to-control diabetes. It is scheduled for presentation at the Cardiometabolic Health Congress on October 15-16, 2026. Separate research on Gvoke prescribing practices was presented October 9, and an analysis of hypothyroidism patients using levothyroxine is scheduled for November 6.
